Logo image of ALDMS.PA

DIAGNOSTIC MEDICAL SYSTEMS (ALDMS.PA) Stock Fundamental Analysis

EPA:ALDMS - Euronext Paris - Matif - FR0012202497 - Common Stock - Currency: EUR

1.065  +0.01 (+1.43%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ALDMS. ALDMS was compared to 55 industry peers in the Health Care Equipment & Supplies industry. ALDMS may be in some trouble as it scores bad on both profitability and health. ALDMS is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALDMS has reported negative net income.
In the past year ALDMS had a positive cash flow from operations.
ALDMS had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: ALDMS reported negative operating cash flow in multiple years.
ALDMS.PA Yearly Net Income VS EBIT VS OCF VS FCFALDMS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -2M -4M -6M

1.2 Ratios

With a Return On Assets value of -20.47%, ALDMS is not doing good in the industry: 67.27% of the companies in the same industry are doing better.
ALDMS has a Return On Equity of -91.77%. This is in the lower half of the industry: ALDMS underperforms 76.36% of its industry peers.
Industry RankSector Rank
ROA -20.47%
ROE -91.77%
ROIC N/A
ROA(3y)-9.88%
ROA(5y)-9.76%
ROE(3y)-34.73%
ROE(5y)-31.23%
ROIC(3y)N/A
ROIC(5y)N/A
ALDMS.PA Yearly ROA, ROE, ROICALDMS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -10 -20 -30 -40

1.3 Margins

Looking at the Gross Margin, with a value of 38.00%, ALDMS is doing worse than 74.55% of the companies in the same industry.
In the last couple of years the Gross Margin of ALDMS has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for ALDMS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 38%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.44%
GM growth 5Y-0.18%
ALDMS.PA Yearly Profit, Operating, Gross MarginsALDMS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20

More info and screens

1

2. Health

2.1 Basic Checks

ALDMS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALDMS has more shares outstanding
The number of shares outstanding for ALDMS has been increased compared to 5 years ago.
Compared to 1 year ago, ALDMS has a worse debt to assets ratio.
ALDMS.PA Yearly Shares OutstandingALDMS.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
ALDMS.PA Yearly Total Debt VS Total AssetsALDMS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of 0.76, we must say that ALDMS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.76, ALDMS is doing worse than 60.00% of the companies in the same industry.
ALDMS has a debt to FCF ratio of 14.05. This is a negative value and a sign of low solvency as ALDMS would need 14.05 years to pay back of all of its debts.
ALDMS's Debt to FCF ratio of 14.05 is in line compared to the rest of the industry. ALDMS outperforms 54.55% of its industry peers.
ALDMS has a Debt/Equity ratio of 1.10. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of ALDMS (1.10) is worse than 81.82% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.1
Debt/FCF 14.05
Altman-Z 0.76
ROIC/WACCN/A
WACC6.16%
ALDMS.PA Yearly LT Debt VS Equity VS FCFALDMS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 5M 10M 15M 20M

2.3 Liquidity

ALDMS has a Current Ratio of 1.29. This is a normal value and indicates that ALDMS is financially healthy and should not expect problems in meeting its short term obligations.
ALDMS has a Current ratio (1.29) which is comparable to the rest of the industry.
ALDMS has a Quick Ratio of 1.29. This is a bad value and indicates that ALDMS is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.64, ALDMS is not doing good in the industry: 72.73% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.29
Quick Ratio 0.64
ALDMS.PA Yearly Current Assets VS Current LiabilitesALDMS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

5

3. Growth

3.1 Past

ALDMS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1661.74%.
Looking at the last year, ALDMS shows a quite strong growth in Revenue. The Revenue has grown by 17.81% in the last year.
ALDMS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.62% yearly.
EPS 1Y (TTM)-1661.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-143.42%
Revenue 1Y (TTM)17.81%
Revenue growth 3Y9.4%
Revenue growth 5Y11.62%
Sales Q2Q%9.89%

3.2 Future

Based on estimates for the next years, ALDMS will show a very strong growth in Earnings Per Share. The EPS will grow by 128.94% on average per year.
The Revenue is expected to grow by 10.93% on average over the next years. This is quite good.
EPS Next Y100%
EPS Next 2Y246.41%
EPS Next 3Y128.94%
EPS Next 5YN/A
Revenue Next Year10.02%
Revenue Next 2Y13.21%
Revenue Next 3Y10.93%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ALDMS.PA Yearly Revenue VS EstimatesALDMS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M 50M
ALDMS.PA Yearly EPS VS EstimatesALDMS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.05 -0.05 0.1 -0.1 -0.15

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALDMS. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 10.34, which indicates a very decent valuation of ALDMS.
85.45% of the companies in the same industry are more expensive than ALDMS, based on the Price/Forward Earnings ratio.
ALDMS is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.10, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 10.34
ALDMS.PA Price Earnings VS Forward Price EarningsALDMS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

ALDMS's Enterprise Value to EBITDA ratio is in line with the industry average.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ALDMS indicates a rather cheap valuation: ALDMS is cheaper than 94.55% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 14.65
EV/EBITDA 43.84
ALDMS.PA Per share dataALDMS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ALDMS's earnings are expected to grow with 128.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y246.41%
EPS Next 3Y128.94%

More info and screens

0

5. Dividend

5.1 Amount

ALDMS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DIAGNOSTIC MEDICAL SYSTEMS

EPA:ALDMS (3/7/2025, 7:00:00 PM)

1.065

+0.01 (+1.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners5.25%
Ins Owner ChangeN/A
Market Cap19.28M
Analysts86.67
Price Target1.84 (72.77%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 10.34
P/S 0.44
P/FCF 14.65
P/OCF 14.65
P/B 1.74
P/tB N/A
EV/EBITDA 43.84
EPS(TTM)-0.54
EYN/A
EPS(NY)0.1
Fwd EY9.67%
FCF(TTM)0.07
FCFY6.83%
OCF(TTM)0.07
OCFY6.83%
SpS2.44
BVpS0.61
TBVpS-0.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.47%
ROE -91.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 38%
FCFM 2.98%
ROA(3y)-9.88%
ROA(5y)-9.76%
ROE(3y)-34.73%
ROE(5y)-31.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.44%
GM growth 5Y-0.18%
F-Score3
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 1.1
Debt/FCF 14.05
Debt/EBITDA 15.34
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion 166.37%
Profit Quality N/A
Current Ratio 1.29
Quick Ratio 0.64
Altman-Z 0.76
F-Score3
WACC6.16%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1661.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-143.42%
EPS Next Y100%
EPS Next 2Y246.41%
EPS Next 3Y128.94%
EPS Next 5YN/A
Revenue 1Y (TTM)17.81%
Revenue growth 3Y9.4%
Revenue growth 5Y11.62%
Sales Q2Q%9.89%
Revenue Next Year10.02%
Revenue Next 2Y13.21%
Revenue Next 3Y10.93%
Revenue Next 5YN/A
EBIT growth 1Y-80.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year480%
EBIT Next 3Y123.74%
EBIT Next 5YN/A
FCF growth 1Y190.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y190.51%
OCF growth 3YN/A
OCF growth 5YN/A